exwannabe,
Funny how a story about how to create a winner out of something initially tanking with then real skin in the game by that initial big investment, comparatively speaking to the period, gets turned into selfish Linda when all those precipitous years advanced into a pathway for all to benefit from while Linda eliminated her financial risk. I don’t see you complaining about those here playing with house money. Why not? Linda is playing with house money too and most current investors, if not all here, came in well after she made the initial big outlay where her risk was in play.
No one was forced to join in this venture and everyone in this sector has to know that development time is a big unknown that CEOs are legally allowed opportunity to underestimate, cover up with plausible deniability and obfuscate about with word salad forward looking statements. Lawyers are good at that and even been known to step on or strategically just over the line at times to keep their businesses or client businesses solvent. This is a surprise?; ).
In a perfect world all good health care ideas showing promise would get sufficient initial time period low rate federal financing continued when basic milestones are met, investors would not see their stock illegally manipulated by those seeking to benefit from an unfair advantage without good legal counter measures or tracking available and big pharma would offer a fair development offer early on based on product potential refined by product performance over time.
You can do better and longs know that right now is a great time to be invested or more invested. The science can be bad mouthed by those who have no credentials or those compromised with little to no effect on longs. Others can belittle this management team or make them out to just be self serving. That requires a totally blind eye be turned to the herculean effort that got this trial data and all other required scrit to inches from the finish line with the lean to the tape seemingly in slow motion after such a long wait. Will you really claim to be out this time like last time when this goes 10X plus from here/now this coming 365 as this ticker coils?; ).
This is going to be fun to watch. Approval, manufacturing, proteomics, tissue agnostic, combo trials and Direct all on the table at the same time as realistic nearer term than longer term. Global manufacturing scale up with potential partners CRL, MRK, BMY and others and reimbursement in the U.K. lining up with approval, all set to bring hope and promise for cancer patients into reality and you want me to look at two CDMOs that could get swallowed up in all the positioning? You gotta be kidding me!; ). Best wishes.
AI
Market Data 
Markets 
